Baxa Corporation Introduces New PhaSeal® System Component For Accessing Needleless Connectors
Baxa Corporation announces the release of the new PhaSeal System Connector, which attaches a PhaSeal Injector to an IV line for safe administration of hazardous drugs. The new Luer Lock Connector was redesigned in response to customer requests for a closed system that can be used with needleless IV access devices. The new connector is longer, to accommodate valve-actuated access devices, while ensuring that the injector needle is never exposed.
Englewood, CO (PRWEB) May 2, 2005 -- Baxa Corporation announces the release
of the new PhaSeal System Connector, which attaches a PhaSeal Injector to an IV
line for safe administration of hazardous drugs. The new Luer Lock Connector was
redesigned in response to customer requests for a closed system that can be used
with needleless IV access devices. The new connector is longer, to accommodate
valve-actuated access devices, while ensuring that the injector needle is never
exposed.
The PhaSeal System is a set of disposable containment devices
that connect the original drug vial, syringe and IV injection or infusion set
together for a completely sealed drug pathway. The system’s double membrane
provides dry connections between system components, preventing drug leakage.
Because PhaSeal is a closed system, hazardous drugs are contained throughout the
entire process of drug transfer, preparation, transport, administration and
disposal. The new connector ensures that the PhaSeal System remains closed, even
with unique valve-actuated IV line access devices.
“The PhaSeal System is
the only documented, closed system for safe handling of antineoplastics and
other hazardous drugs,” affirms Agneta Ekblad, RN, Vice President, Oncology
Solutions for Baxa Corporation. Closed systems have been recommended by the
National Institute for Occupational Safety and Health (NIOSH) and the Oncology
Nurses Society to provide an engineering control against environmental and
personal contamination. An Alert published by NIOSH in March 2004 details
research describing the significant health risks related to handling, mixing and
administering hazardous drugs. The document recommends a number of measures to
reduce or eliminate human exposure to these toxic hazards in the
workplace.
The new PhaSeal Connectors are currently in inventory, and
replace the previously sold connectors. Products are available directly from
Baxa Corporation and also through medical products wholesalers, under the
original order numbers.
About Baxa Corporation
Celebrating 30 years of
business in 2005, Baxa Corporation is a Denver-based manufacturer of medical
devices and systems for preparing, handling, packaging, and administering liquid
medications. The company manufactures and markets a wide range of healthcare
products for use in hospitals, critical care units and alternate-site
pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices
in Canada, the United Kingdom; Denmark, and Germany; and distribution partners
worldwide. Further information is available at http://www.baxa.com.
About Carmel Pharma ab
The
PhaSeal System is manufactured in Sweden by Carmel Pharma ab of Göteborg,
Sweden. Introduced in Europe in 1994, the PhaSeal System is used in most Swedish
hospitals, with its benefits documented by a significant body of scientific
research on the health risks associated with the preparation and administration
of cytotoxic drugs. The PhaSeal System is protected by a comprehensive patent
portfolio in the U.S., European Union and Japan. For more information on Carmel
Pharma, please visit http://www.carmelpharma.se.
Click the following link to
view a presentation by Jim Jorgenson "Using a Closed System Device to Reduce
Occupational Exposure to Hazardous Drugs." Jorgenson is Director of Pharmacy for
the Huntsman Cancer Institute and Associate Dean for Professional Affairs at the
University of Utah:
http://www.isips.org/presentations/PhaSeal/player.html
"What
if the Cure is Also a Cause?
The Same Chemo Drugs That Save Some Cancer
Patients' Lives Put Health Workers at Risk"
A Major Daily Newspaper Looks at
this Issue in Depth: February 15, 2005
http://www.washingtonpost.com/wp-dyn/articles/A24458-2005Feb14.html?referrer=emailarticle
Contacts:
Marian
Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157
or 303.617.2157
Email: e-mail protected from spam bots
Maggie
Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or
303.669.3558
Email: e-mail protected from spam bots
# # #
Source : http://www.prweb.com/releases/2005/5/prweb235303.htm